MTOR and type 2 diabetes mellitus: Advanced glycosylation end products (AGEs) are a group of substances existing in poorly controlled type 2 diabetes mellitus, which promote the fibrotic response of VSMCs and then aggravate AS through mTOR signaling pathway activation (de Vos et al., 2016).